Company Overview and News
LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Valeant Pharmaceuticals International, Inc. (NYSE: VRX) ("Valeant"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=VRX. The Company announced on November 10, 2017, that it has completed the sale of the Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L. (270-1)
Good morning, ladies and gentlemen and welcome to the Bio-Path Holdings Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we’ll open up the call to your questions. (54-0)
Bio-Path Holdings, Inc. (Bio-Path) is a clinical stage biotechnology company that focuses on developing nucleic acid cancer therapeutics using its proprietary nanoparticle RNAi antisense technology called DNAbilize®. This technology safely distributes nucleic acid based drugs systemically throughout the body via intravenous infusion. Bio-Path's lead product candidate, prexigebersen (BP1001) is in Phase 2 clinical studies for the treatment of acute and chronic myeloid leukemia (AML and CML), and preclinical studies for solid tumors. (54-0)
If you want a Stock Review on AMAG, IDXX, PTN, or BPTH then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today's attention is directed to the Healthcare sector, which is the category of stocks relating to medical and healthcare goods or services. The sector includes hospital management firms, health maintenance organizations, biotechnology, and a variety of medical products. (174-1)
HOUSTON, Aug. 15, 2017 /PRNewswire/ -- Compressor Engineering Corporation (CECO) & CECO Pipeline Services recently announced that Heath Cleaver has been named the company's Chief Financial Officer.
Glioblastoma Multiforme Pipeline Therapeutics Development 2017 report provides Companies Involved in Therapeutics Development like AbbVie, Novartis AG, Novogen, Merck KGaA and others. Report encapsulates all the dormant and discontinued Glioblastoma Multiforme pipeline projects.
DALLAS, TX / ACCESSWIRE / June 29, 2017 / Stonegate Capital Partners updates research coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH).
RnRMarketResearch.com adds "Myelodysplastic Syndrome Pipeline Review H1 2017" therapeutic market research report provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline.
Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open up the call for your questions.
It has been about a month since the last earnings report for Infinity Pharmaceuticals, Inc. (INFI - Free Report) . Shares have lost about 37.4% in that time frame, underperforming the market.
AMAG Pharmaceuticals, Inc. (AMAG - Free Report) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S. Makena is currently approved as an intramuscular (IM) injection to reduce the risk of preterm birth in women who are pregnant with one baby.
Infinity Pharmaceuticals, Inc. (INFI - Free Report) was a big mover last session, as the company saw its shares rise over 19% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This reverses the recent trend for the company, as the stock is now down nearly 36% since Mar 29.
Bio-Path Holdings, Inc. (BPTH - Free Report) was a big mover last session, as the company saw its shares rise over 13% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This reverses the downtrend for the company, as the stock is now down nearly 32% in the past one-month time frame.
Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Year-End 2016 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions.
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton